Ensuring the Affordable Becomes Accessible – Lessons from Ketamine’s Antidepressant Development and a Vision for More Equitable Drug Development

In this guest contribution, Dilara Bahceci, PhD, explores the confluence of economic, regulatory and research-related barriers that have conspired to effectively disincentivise the development of generic ketamine for depressive disorders.Drawing on a recent article she co-authored with colleagues in Australia (Rodgers et al., 2023), Dr. Bahceci sheds light on the story of Spravato’s commercial…

Source